Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus et al. · New England Journal of Medicine · 2013 · 1.5K citations · Full text

VEGF Inhibition and Renal Thrombotic Microangiopathy

Vera Eremina, J. Ashley Jefferson, Jolanta Kowalewska et al. · New England Journal of Medicine · 2008 · 1.5K citations · Full text

Glomerular Disease, Immunology, Pathology +19

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

Vera Eremina, Manish M. Sood, Jody J. Haigh et al. · Journal of Clinical Investigation · 2003 · 1.3K citations

Glomerular Disease, Renal Pathology, Renal Inflammation +25

A Conditionally Immortalized Human Podocyte Cell Line Demonstrating Nephrin and Podocin Expression

Moin A. Saleem, Michael J. O’Hare, Jochen Reiser et al. · Journal of the American Society of Nephrology · 2002 · 1.1K citations

Cell Physiology, Protein Function, Developmental Biology +14

Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice

Vernon L. Tesh, J A Burris, Jackie Owens et al. · Infection and Immunity · 1993 · 384 citations · Full text

Immunotoxicology, Toxinology, Immunology +18